Supreme Court Gives Tacit Approval for Government to Take Anybody’s DNA
By David Kravets,
Ars Technica
| 03. 02. 2015
Untitled Document
The Supreme Court on Monday let stand the conviction of a rapist whose prosecution rested on DNA swiped from the armrests of an interrogation-room chair.
Without comment, the justices refused to review a 4-3 decision from Maryland's top court that upheld the life sentence and conviction of Glenn Raynor. The dissent on the Maryland Court of Appeals said a probable-cause warrant was needed and painted a grim picture of the future:
The Majority’s approval of such police procedure means, in essence, that a person desiring to keep her DNA profile private, must conduct her public affairs in a hermetically sealed hazmat suit.... The Majority's holding means that a person can no longer vote, participate in a jury, or obtain a driver's license, without opening up his genetic material for state collection and codification.
In urging the high court to review the case, the Electronic Frontier Foundation wrote that "allowing police the limitless ability to collect and search genetic material will usher in a future where DNA may be collected from any person at any time, entered into and checked against DNA...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...